According to the ASAS/EULAR guidelines, the patient's response to third-line treatment, in this case with a second TNF inhibitor, should be assessed after at least 12 weeks of therapy. The decision to continue therapy is based on evidence of substantially decreased disease activity (ie, improvement in ASDAS ≥ 1.1) and the clinician's opinion.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Marina Magrey. Skill Checkup: A 44-Year-Old Man With Moderate to Severe Lower Back Pain Despite Treatment - Medscape - Apr 05, 2023.